Wedbush Issues Positive Forecast for Biogen (NASDAQ:BIIB) Stock Price

Biogen (NASDAQ:BIIB) had its target price raised by Wedbush from $187.00 to $191.00 in a report issued on Wednesday,MarketScreener reports. The brokerage currently has a neutral rating on the biotechnology company’s stock.

A number of other research firms have also recently weighed in on BIIB. Oppenheimer upped their price target on Biogen from $250.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday. Stifel Nicolaus raised their price objective on Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a report on Friday, February 6th. Wells Fargo & Company boosted their price objective on Biogen from $190.00 to $200.00 and gave the company an “equal weight” rating in a research report on Sunday, February 8th. Truist Financial upped their target price on Biogen from $190.00 to $193.00 and gave the stock a “hold” rating in a research note on Monday, February 9th. Finally, Citigroup increased their target price on Biogen from $185.00 to $215.00 and gave the company a “neutral” rating in a research report on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Biogen presently has an average rating of “Hold” and a consensus target price of $207.96.

Biogen Stock Up 0.2%

BIIB stock opened at $183.78 on Wednesday. Biogen has a one year low of $110.04 and a one year high of $202.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The firm’s fifty day moving average is $186.41 and its 200 day moving average is $171.07. The firm has a market cap of $26.97 billion, a PE ratio of 20.86, a P/E/G ratio of 1.46 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the prior year, the firm posted $3.44 earnings per share. The company’s revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, research analysts forecast that Biogen will post 15.83 EPS for the current year.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.18% of the stock is owned by company insiders.

Institutional Trading of Biogen

Several large investors have recently bought and sold shares of BIIB. Elevation Point Wealth Partners LLC acquired a new stake in Biogen in the 2nd quarter valued at about $25,000. Reflection Asset Management acquired a new position in shares of Biogen during the 4th quarter worth approximately $25,000. WPG Advisers LLC grew its position in shares of Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares in the last quarter. Accredited Wealth Management LLC grew its position in shares of Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 185 shares in the last quarter. Finally, First Horizon Corp acquired a new stake in shares of Biogen in the fourth quarter valued at approximately $30,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen agreed to acquire Apellis for about $5.6 billion in cash, bringing two commercial immunology/rare‑disease drugs (SYFOVRE®, EMPAVELI®) and a nephrology launch capability — expected to boost near‑term revenue and diversify Biogen beyond MS. Biogen to buy Apellis Pharmaceuticals for $5.6 billion (Reuters)
• Positive Sentiment: Analysts reacted with higher price targets and constructive coverage: Oppenheimer raised its PT to $275 (outperform) and Canaccord to $245 (buy), lifting sentiment that the deal and other pipeline wins improve Biogen’s growth profile. Oppenheimer raises Biogen price target (MarketScreener)
• Positive Sentiment: FDA approval of a higher‑dose SPINRAZA regimen supports Biogen’s rare‑disease revenues and reduces competitive risk in SMA, adding another near‑term commercial tailwind alongside Apellis assets. Biogen secures FDA nod for higher‑dose SPINRAZA (Zacks)
• Neutral Sentiment: Biogen management says combined cash flow from Biogen + Apellis should improve leverage ratios and free capacity for further deals — management framing the purchase as strategic rather than one‑off. Biogen CFO comments on cash flow and M&A capacity (BioPharmaDive)
• Neutral Sentiment: Apellis shares surged (more than doubled) on the takeover premium; that rally reflects deal certainty for Apellis but only partially signals upside for Biogen beyond the strategic rationale. Apellis hits multi‑year high on Biogen deal (Yahoo Finance)
• Negative Sentiment: An investor law firm has opened an investigation into the adequacy of the Apellis sale price/process, which could signal proxy litigation or shareholder pushback that complicates or delays closing. Investor investigation into Apellis sale process (BusinessWire)
• Negative Sentiment: Some analysts remain cautious (Hold ratings cited), pointing to execution risk on Leqembi/ MS erosion, integration risk and the cash outflow’s near‑term impact — these concerns help explain any initial pressure on Biogen shares after the deal news. Analyst caution/hold ratings despite positives (TipRanks)

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.